Corautus Genetics angina drug fails to meet goal

The endpoint in the clinical trial was an improvement of at least one minute in exercise tolerance time from baseline to three months. The data indicated considerable overlap in results between the active and placebo groups for the secondary endpoints as well, and no clear dose effect was seen.

The final data from the trial has now been received and studied, the company said.

“In general, a majority of patients in all treatment arms (active and placebo) significantly improved from their baseline status in both primary and secondary efficacy endpoints; however, there was no significant separation from the placebo in any active dose group,” said Richard Otto, president and CEO of Corautus.

“We continue to support phase I clinical trials involving VEGF-2 for both diabetic neuropathy and critical limb ischemia, but we have also actively focused recent efforts on identifying additional therapeutic development opportunities for Corautus via in-license, merger or acquisition,” he added.